The process involves using specific mechanisms such as antibodies, nanoparticles, or ligands that bind to unique markers on cancer cells. These markers are often proteins or receptors that are overexpressed on the surface of cancer cells. Once the drug-carrier complex binds to these markers, the drug is released directly into the cancer cell, sparing healthy tissue.
